











doi:10.101Interleukin 17 Is Not Required for Autoimmune-
Mediated Pathologic Damage during Chronic
Graft-versus-Host Disease
Xiao Chen,1,2 Rupali Das,1,3 Richard Komorowski,4 Jacques van Snick,5
Catherine Uyttenhove,5 William R. Drobyski1,2,3The transition from acute to chronic graft-versus-host disease (aGVHD, cGVHD) is characterized by the
progressive loss of self-tolerance and the development of autoimmune manifestations. Interleukin 17 (IL-
17) is a proinflammatory cytokine that has been shown to play a prominent role in autoimmune disorders
in the nontransplant setting, but the extent to which IL-17 is necessary for the autoimmunity that occurs
as a consequence of GVHD is not known. In this study, we demonstrate using a combination of antibody-
based and genetic approaches that IL-17 is not required for the loss of self-tolerance and resulting
CD41 T cell-dependent pathologic damage that occurs during the evolution from aGVHD to cGVHD.
Rather, TH1 cells and other proinflammatory cytokines are fully competent to promote autoimmune-
mediated tissue damage. Thus, the selective targeting of IL-17 may not be a viable clinical strategy for
preventing the autoimmune manifestations that develop during cGVHD.
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Graft-versus-host disease (GVHD) is characterized
by the overproduction of inflammatory cytokines that
mediate tissue damage, activate secondary effector
cells, and induce the differentiation of proinflammatory
T cells from naı¨ve T cells [1-4]. Interleukin 17 (IL-17)
is one such inflammatory cytokine that has been identi-
fied in the serum and tissues of allograft recipients
with GVHD [5,6], although the extent to which this
cytokine is required for the induction of pathology
during GVHD remains unresolved. Recent studies
have demonstrated that transplantation of a highly
purified TH17 cell population can cause acute
GVHD (aGVHD)-related pathologic damage with tis-
sue predilection for the skin and lung [7]. However,
studies using IL-17-deficient mice as donors in trans-
plantation experiments have yielded divergent results1Bone Marrow Transplant Program2Department of Med-
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rious effects during aGVHD [6,8]. The role of IL-17 in
chronic GVHD (cGVHD), where autoimmune-like
manifestations are a defining characteristic of the dis-
ease [9-11], has not been examined even though IL-17
has been directly implicated in the pathophysiology of
other autoimmune disorders [12,13]. In previous stud-
ies, we [5] and others [14], using different murine
models, have demonstrated that TH17 cells are present
in target organs of animals that develop GVHD-
associated autoimmune-mediated pathologic damage.
However, whether IL-17 is required for the induction
of pathology or whether this cytokine is dispensable
was not resolved. In the current report, we employed
a previously described BMT model [5,15] that is char-
acterized by loss of self-tolerance and the development
of autoimmunity, which are hallmarks of cGVHD in
human allogeneic stemcell transplant recipients [9-11],
to examine whether IL-17 is required for the develop-
ment of autoimmune-mediated pathologic damage.METHODS
Mice
C57BL/6 (B6) (H-2b), Balb/cJ (H-2d), and
B6.129S7-Rag 1 (B6 Rag) mice were bred in the Ani-
mal Resource Center at the Medical College of
Wisconsin (MCW) or purchased from Jackson123
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(IL-17–/–) on a B6 background were obtained from
Dr. Yoichiro Iwakura (University of Tokyo, Tokyo,
Japan). All animals were housed in the Association
for the Assessment and Accreditation of Laboratory
Animal Care-accredited Animal Resource Center of
the MCW. Experiments were all carried out under
protocols approved by the MCW Institutional Animal
Care and Use Committee. Mice received regular
mouse chow and acidified tap water ad libitum.
Bone Marrow (BM) Transplantation
BM was flushed from donor femurs and tibias with
Dulbecco’s modified media (DMEM) and passed
through sterilemesh filters to obtain single cell suspen-
sions. Host mice were conditioned with total body
irradiation (TBI) administered as a single exposure at
a dose rate of 67 cGy using a Shepherd Mark I Cesium
Irradiator (J.L. Shepherd and Associates, San Fer-
nando, CA). Irradiated recipients received a single in-
travenous injection in the lateral tail vein of BM and
spleen cells in a total volume of 0.4 mL. In adoptive
transfer experiments, nonirradiated B6 Rag mice
received splenocytes from previously irradiated, fully
donor-engrafted B6/ Balb/c chimeras 19-21 days
posttransplantation. Typically, 30% to 40% of trans-
ferred spleen cells were comprised of donor T cells.
Flow Cytometry
Monoclonal antibodies (mAb) conjugated to fluo-
rescein isothiocyanate (FITC), phycoerythrin (PE),
or phycoerythrin-Cy5 (PE-Cy5) were used to assess
cell populations and were purchased from BD Biosci-
ences Pharmingen (San Diego, CA). For intracellular
staining, lymphocytes isolated from spleen, liver, and
colon were stimulated with 50 ng/mL PMA (Sigma,
St Louis, MO) and 750 ng/mL ionomycin (Calbio-
chem, La Jolla, CA) for 2.5 hours and then incubated
with GolgiStop (BD Pharmingen) for an additional
2.5 hours. Cells were analyzed on a FACSCalibur
flow cytometer with Cellquest software (Becton-
Dickenson, Fullerton, CA). Data were analyzed using
FlowJo (Treestar, Ashland, OR).
Reagents
Anti-IL-17 antibody (MM17F3) is a mouse IgG1
that has been previously described [16,17]. Animals
received 200 mg of antibody twice weekly by intraper-
itoneal injection. Antibody was resuspended in phos-
phate-buffered saline (PBS) prior to injection. Mouse
IgG1 (Sigma) was used as a control and administered
at the same dose and schedule as MM17F3.
Histologic Analysis
Representative samples of liver, colon, and lung
were obtained from transplanted recipients and fixedin 10% neutral-buffered formalin. Samples were then
embedded in paraffin, cut into 5-micron-thick sec-
tions, and stained with hematoxylin and eosin. A semi-
quantitative scoring system was employed to account
for histologic changes in the colon, liver, and lung as
previously described [18]. All slides were coded and
read in a blinded fashion. Images were visualized
with an Olympus BX45 microscope (Tokyo, Japan).
Image acquisition was performed with an Olympus
DP70 digital camera and software package.
Serum Cytokine Analysis
Serum was collected from mice by retroorbital
bleeds and analyzed on a Bioplex System (BioRad Lab-
oratories, Hercules, CA) according to the manufac-
turer’s instructions. All samples were run in duplicate.
Cell Isolation
To isolate lamina propria lymphocytes (LPLs),
pooled colons were incubated with EDTA for 30 min-
utes at 37C and cells were then passed through a
100-micron strainer to remove cellular debris. The re-
maining colon tissue was cut into smaller pieces and
incubated in PBS containing 2% fetal bovine serum
and 0.15 mg/mL collagenase D (Roche Diagnostics,
Mannheim, Germany) for 75 minutes at 37C. The
cell suspension was then filtered through a 100-m
strainer and layered on a 44%/67% Percoll gradient.
Liver lymphocytes were isolated by collagenase D
digestion followed by layering on a Percoll gradient.
Statistics
Group comparisons of T cell populations, cyto-
kine levels, and pathology scores were performed using
the Mann Whitney U-test or Student t-test. A P-value
#.05 was deemed to be significant in all experiments.RESULTS AND DISCUSSION
Blockade of IL-17 Signaling Has No Protective
Effect on the Autoimmune-Mediated Pathologic
Damage That Occurs During cGVHD
To define the role of IL-17 in cGVHD, lethally ir-
radiated Balb/c mice were first transplanted with B6
BM along with 0.4-0.5 106 B6 spleen cells to induce
aGVHD. Approximately 19-21 days posttransplanta-
tion, spleen cells (0.45-0.5 106) from fully donor-
engrafted animals were adoptively transferred into
nonirradiated syngeneic B6 Ragmice. These mice typ-
ically develop autoimmune-mediated tissue damage in
the colon, liver, and lung within 45 to 60 days. Cohorts
of these animals were treated with either isotype con-
trol or anti-IL-17 antibody twice weekly, beginning
at the time of transfer. This antibody administration
schedule was based on published studies that showed
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animals from developing experimental allergic en-
cephalomyelitis [16]. All mice survived the duration
of these studies and were evaluable for analysis. Exam-
ination of target organ tissues revealed no significant
differences in pathology scores in the colon, liver, or
lung in mice treated with isotype versus anti-IL-17
antibody (Figure 1A and B). Furthermore, there was
no statistically significant difference in overall spleen
cellularity and myeloid expansion (Figure 1C), which
are hallmarks of autoimmunity in this model [15].
Examination of serum proinflammatory cytokine
levels also revealed no differences with the exception
of granulocyte-colony stimulating factor (G-CSF),Figure 1. Blockade of IL-17 signaling has no protective effect on the
(900 cGy) Balb/c mice were transplanted with B6 bonemarrow (BM) (10 106
mice were sacrificed and spleen cells from fully donor-engrafted animals (0.45-
B6 Rag animals were then treated with either IgG1 isotype control or anti-IL-17
posttransfer. (A) Pathologic damage in the colon, liver, and lung of mice treate
using a semiquantitative scoring system as detailed in the Methods section. (B)
with either isotype or anti-IL-17 antibody. In isotype control animals, colon sh
reveals portal triad inflammation with mononuclear cells and endothelialitis,
anti-IL-17 antibody-treated mice, colon also shows extensive inflammation in t
has portal triad inflammation and lung demonstrates perivascular cuffing. (C) T
are depicted. (D) Serum proinflammatory cytokine levels from B6 Rag mice tr
ately prior to sacrifice of animals. (E) Absolute number of CD41 and CD81 T
antibody (n5 9) 48 to 69 days posttransfer. (F) Spleens and colon tissue from a
were pooled and the percentage of CD41 T cells secreting IL-17, IFN-g, or bot
the cumulative results from 3 to 4 independent experiments for all studies dewhich was significantly reduced in animals treated
with anti-IL-17 antibody consistent with the previ-
ously described effects of IL-17 on granulopoiesis
[19-21] (Figure 1D). Studies were then done to deter-
mine whether blockade of IL-17 affected the genera-
tion of TH1 and TH17 cells in the spleen and colon
of these same animals because pathologic damage in
this model is CD41 T cell dependent [5]. The absolute
number of splenic CD41 T cells, although signifi-
cantly increased relative to CD81 T cells, did not
differ between groups (Figure 1E). Moreover, no dif-
ference was observed in the percentage of CD41IL-
171 or CD41IFN-g1 T cells in either the spleen or
the colon of anti-IL-17 versus isotype antibody-treateddevelopment of autoimmunity during cGVHD. Lethally irradiated
) plus 0.4-0.5 106 B6 spleen cells. On days 19 to 21 posttransplantation,
0.5 106) were transferred into nonirradiated B6 Rag mice. Cohorts of
antibody (200 mg/dose) twice weekly. Mice were sacrificed 48 to 75 days
d with isotype control (-, n5 12) or anti-IL-17 antibody (,, n5 12)
Histology of colon, liver, and lung from representative recipients treated
ows inflammation in the lamina propria, and goblet cell depletion, liver
and lung demonstrates perivascular cuffing with mononuclear cells. In
he lamina propria, goblet cell depletion, and crypt cell destruction, liver
otal cellularity and absolute number of Gr-11 Mac-11 cells in the spleen
eated with either isotype (n5 9) or anti-IL-17 antibody (n5 9) immedi-
cells in the spleens of mice administered isotype (n5 9) or anti-IL-17
nimals that received either control or anti-IL-17 antibody (n5 3/group)
h, in each organ is shown. Data are presented as the mean6 SEM and are
picted. Statistics: *P # .05. **P # .01;
Figure 2. Absence of donor-derived IL-17 has no protective effect on the development of autoimmunity. Lethally irradiated Balb/c mice
were transplanted with BM (10 106) and spleen cells (0.4 106) from wild-type B6 or IL-172/2 animals to induce GVHD. Mice from each group were
sacrificed 19 to 21 days after transplantation and pooled spleen cells (0.5 106) were transferred into nonirradiated B6 Ragmice. (A) Representative dot
plot depicting the percentage of IL-17 and/or IFN-g-secreting cells within the gated CD41 T cell population obtained from the spleen, liver, or colons of
mice 60 to 65 days after transfer of spleen cells from B6/ Balb/c or IL-172/2/ Balb/c chimeras. (B,C) Individual spleens, liver, and colon tissue fromB6
Rag mice that received adoptive transfer of spleen cells from B6/ Balb/c (-) or IL-172/2/ Balb/c (,) chimeras (n5 2-4/group) were pooled and
the percentage (B) and absolute number (C) of CD41 T cells secreting IFN-g in each organ is depicted. Data are the cumulative results from 3 inde-
pendent experiments. Each experiment had the same number of mice per group. (D) Individual spleens, livers, and colon tissue from B6 Rag mice that
received adoptive transfer of spleen cells from B6/ Balb/c or IL-172/2/ Balb/c chimeras (n5 2-4/group) were pooled and the percentage of CD41 T
cells secreting IL-17 in each organ is depicted. (E) Pathologic damage in the colon, liver and lung of mice 60-65 days after adoptive transfer of spleen cells
from B6/ Balb/c (n5 9) or IL-172/2/ Balb/c (n5 9) chimeras. Data are the cumulative results from 3 independent experiments. Data are presented
as the mean6 SEM. Statistics: *P # .05.
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administration did not appear to alter the differentia-
tion of naı¨ve T cells into IL-17 or IFN-g-secreting
CD41 T cells. The fact that antibody administration
did not result in a decrease in the absolute numbersof TH17 cells was not unexpected given previous
data that has shown that transforming growth facg-
tor-beta (TGF-b) and IL-6, but not IL-17 itself, are
required for the differentiation of naı¨ve T cell into
TH17 cells [22,23].
Biol Blood Marrow Transplant 16:123-128, 2010 127Role of Interleukin 17 in Chronic GVHDAutoimmune-Mediated Pathology Is Not
Abrogated in the Absence of IL-17 Secreted by
Donor-Derived CD41 T Cells
To confirm these findings, we employed a comple-
mentary approach to examine this question using mice
that were incapable of secreting IL-17 as donors in
adoptive transfer studies. In these experiments, lethally
irradiated Balb/c mice were transplanted with either
B6 or IL-172/2 BM and spleen cells to induce
aGVHD. Approximately 3 weeks posttransplantation,
spleen cells from donor-engrafted B6/ Balb or IL-
172/2/ Balb chimeras were transferred into nonirra-
diated B6 Rag mice. We observed that CD41IFN-g1
T cells were present in both groups of mice, although
there was no statistically significant difference in the
percentage (Figure 2A and B) or absolute number
(Figure 2C) of these cells in the spleen, liver, or colon.
In contrast, examination of these tissues in Rag animals
that received splenocytes from B6/ Balb chimeras
mice revealed defined populations of CD41IL-171 T
cells in all sites, whereas these cells were essentially ab-
sent in mice reconstituted with splenocytes from IL-
172/2/ Balb chimeras (Figures 2A and D). The
absence of CD41IL-171 T cells, however, did not ab-
rogate pathologic damage, as individual tissue-specific
pathology scores were similar in both groups of mice
(Figure 2E).
In summary, using a combination of antibody-
based and genetic approaches, these studies demon-
strate that IL-17 is not required for the induction
of autoimmune-mediated pathologic damage that is
a defining characteristic of cGVHD. These results
support recent studies by Yi and colleagues [6], who
observed that the absence of donor-derived IL-17
had no protective effect during aGVHD and actually
exacerbated the disease. Our data are also consistent
with work by Imanguli et al [24] implicating TH1
cells as major effectors in human cGVHD. In this
study, the authors demonstrated the presence of
Tbet1 T cells with expression of cytotoxic molecules
such as granzyme B in the oral lesions of patients with
cGVHD and concluded that a TH1-mediated process
appeared to be primarily responsible for pathologic
damage. Finally, these studies suggest that a clinical
strategy designed to specifically target IL-17 is un-
likely to significantly modulate the severity of
cGVHD as remaining TH1 cells and other proin-
flammatory cytokines remain fully capable of induc-
ing pathologic damage.ACKNOWLEDGMENTS
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